Find information on thousands of medical conditions and prescription drugs.

Zoladex

Goserelin is an injectable gonadotropin releasing hormone agonist (GnRH agonist). It stops the production of sex hormones (testosterone and oestrogen) and is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction. more...

Home

Zagam

Zantac

Zelnorm

Zerit

Zestoretic

Zestril

Zetia

Zevalin

Ziagen

Zocor

Zofran

Zoladex

Zoledronic acid

Zolmitriptan

Zoloft

Zolpidem

Zometa

Zomig

Zonegran

Zonisamide

Zopiclone

Zosyn

Zovia

Zovirax

Zyban

Zymar

Zyprexa

Zyrtec

Zyvox

It is available as a 1-month depot and a long-acting 3-month depot. Both depots are used for the treatment of prostate cancer, endometriosis and uterine fibroids but only the 1-month depot is approved for breast cancer, endometrial thinning and assisted reproduction.

Goserelin is marketed by AstraZeneca with the brand name Zoladex. It was first launched in 1987 and is currently the second-largest selling LHRHa in the world. It is currently available in more than one hundred markets.

Read more at Wikipedia.org

• [List your site here Free!]


		Current Therapy for Prostate Cancer: Focus on Goserelin : Proceedings of the Zoladex International Symposium September 20-21, 1991, Kobe, Japan (Cur) $304.89


	Zoladex Before Ablation Leads to Better Outcomes ORLANDO, FLA. -- Pretreatment with goserelin acetate improves long-term outcomes in patients undergoing endometrial ablation for dysfunctional uterine ... From OB/GYN News, 4/1/01 by Sharon Worcester

	The truth about fibroids: our guide to the latest in treatment - health Kimberly Reid had always had fairly regular periods. But over the course of a year and a half, the 34-year-old realized her four-to-five-day periods ... From Essence, 9/1/03 by Linda Knittel

	Mitozantrone-induced onycholysis associated with subungual abscesses, paronychia, and pyogenic granuloma Abstract Chemotherapeutic agents may induce a wide variety of adverse mucocutaneous effects, including nail changes. We present a case of atypical ... From Journal of Drugs in Dermatology, 7/1/05 by Anatoli Freiman

	Pharmaco-fakery We've been hearing a lot about counterfeit drugs this month, from thought-provoking sessions at the American Association of Pharmaceutical Scientists' ... From Pharmaceutical Technology, 12/1/04 by Douglas McCormick

	Zoladex marketing nets $355 million fine WILMINGTON, Del. -- AstraZeneca Pharmaceuticals pleaded guilty Friday to violating a federal drug marketing law and will pay $355 million to settle ... From Deseret News (Salt Lake City), 6/21/03 by Randall Chase Associated Press writer

	Why get a second pathology opinion for breast cancer: an interview Of all the tests given to a woman newly diagnosed with breast cancer, one is crucial in determining her treatment plan. It measures the tumor's "hormone ... From Healthfacts, 9/1/04

	Research and Markets: the Endometriosis Market is Expected to Change Dramatically Following the Patent Expiry of Key Brands Lupron Depot, Zoladex and Suprefact DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com) has announced the addition of Pipeline Insight: Endometriosis - Growing the Patient Population is Key to Unlocking the Ma From Business Wire, 9/27/04

	AstraZeneca to pay $355 million fine - Updates AstraZeneca Pharmaceuticals LP of Wilmington, Del., has agreed to pay a $355 million fine to resolve criminal charges and civil liabilities stemming ... From FDA Consumer, 9/1/03

Home

Contact

Resources

Exchange Links

ebay